Furthermore, gene therapy in combination with immunotherapy, e.g., targeting CTLA-4 and PD-1, or with the emerging therapeutic angiogenesis inhibitors, may result in increased effectiveness, especially for ovarian cancer in advanced stages, where still no effective therapies exist. This evidence concerns the gene CTLA4 and ovarian carcinoma.